FDA approves automated insulin delivery and monitoring system for use in children aged 2 to 6 with type 1 diabetes

Approval is for MiniMed 770G System, first-of-a-kind device for this age group, comprising a hybrid closed loop diabetes management device intended to automatically monitor glucose and provide appropriate basal insulin doses with little or no input from users or their caregivers.

Source:

US Food and Drug Administration